Literature DB >> 22407536

Regression analysis based on conditional likelihood approach under semi-competing risks data.

Jin-Jian Hsieh1, Yu-Ting Huang.   

Abstract

Medical studies often involve semi-competing risks data, which consist of two types of events, namely terminal event and non-terminal event. Because the non-terminal event may be dependently censored by the terminal event, it is not possible to make inference on the non-terminal event without extra assumptions. Therefore, this study assumes that the dependence structure on the non-terminal event and the terminal event follows a copula model, and lets the marginal regression models of the non-terminal event and the terminal event both follow time-varying effect models. This study uses a conditional likelihood approach to estimate the time-varying coefficient of the non-terminal event, and proves the large sample properties of the proposed estimator. Simulation studies show that the proposed estimator performs well. This study also uses the proposed method to analyze AIDS Clinical Trial Group (ACTG 320).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407536     DOI: 10.1007/s10985-012-9219-3

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  2 in total

1.  A two-sample comparison for multiple ordered event data.

Authors:  S H Chang
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

2.  Regression modeling of semicompeting risks data.

Authors:  Limin Peng; Jason P Fine
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

  2 in total
  3 in total

1.  Semicompeting risks in aging research: methods, issues and needs.

Authors:  Ravi Varadhan; Qian-Li Xue; Karen Bandeen-Roche
Journal:  Lifetime Data Anal       Date:  2014-04-12       Impact factor: 1.588

2.  Semiparametric model for semi-competing risks data with application to breast cancer study.

Authors:  Renke Zhou; Hong Zhu; Melissa Bondy; Jing Ning
Journal:  Lifetime Data Anal       Date:  2015-09-05       Impact factor: 1.588

3.  SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trials.

Authors:  Yifei Zhang; Beibei Guo; Sha Cao; Chi Zhang; Yong Zang
Journal:  Pharm Stat       Date:  2022-03-24       Impact factor: 1.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.